SC US (TTGP), LTD. - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 209 filers reported holding BRIDGEBIO PHARMA INC in Q2 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.5%.

Quarter-by-quarter ownership
SC US (TTGP), LTD. ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$49,057,799
+53.3%
1,860,3640.0%0.45%
+50.2%
Q2 2023$31,998,261
+3.7%
1,860,3640.0%0.30%
-17.3%
Q1 2023$30,844,835
+117.6%
1,860,3640.0%0.36%
+94.7%
Q4 2022$14,175,974
-23.3%
1,860,3640.0%0.19%
-12.6%
Q3 2022$18,492,000
+9.5%
1,860,3640.0%0.21%
+8.6%
Q2 2022$16,892,000
-10.5%
1,860,3640.0%0.20%
+62.8%
Q1 2022$18,883,000
-39.1%
1,860,3640.0%0.12%
-21.9%
Q4 2021$31,031,000
-64.4%
1,860,3640.0%0.16%
-68.2%
Q3 2021$87,195,000
-23.1%
1,860,3640.0%0.49%
-32.5%
Q2 2021$113,408,000
-27.7%
1,860,364
-26.9%
0.72%
-23.1%
Q1 2021$156,756,000
-13.4%
2,544,7380.0%0.94%
-13.1%
Q4 2020$180,956,000
+89.5%
2,544,7380.0%1.08%
+17.5%
Q3 2020$95,479,000
+15.1%
2,544,7380.0%0.92%
-81.1%
Q2 2020$82,984,000
+12.4%
2,544,7380.0%4.87%
-13.9%
Q1 2020$73,797,000
-17.3%
2,544,7380.0%5.65%
+47.7%
Q4 2019$89,193,000
+63.2%
2,544,7380.0%3.83%
+57.9%
Q3 2019$54,636,000
-20.4%
2,544,7380.0%2.42%
-48.3%
Q2 2019$68,632,0002,544,7384.69%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q2 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 3,835,722$103,449,00044.18%
Kohlberg Kravis Roberts & Co. L.P. 36,900,661$995,211,00012.26%
SC US (TTGP), LTD. 2,544,738$68,632,0004.69%
Cormorant Asset Management, LP 2,780,885$75,000,0004.31%
Perceptive Advisors 6,706,268$180,868,0004.15%
VIKING GLOBAL INVESTORS LP 26,620,991$717,968,0003.22%
Hillhouse Capital Management 2,035,790$54,905,0001.75%
Alpine Group USVI, LLC 20,000$539,0001.70%
HHLR ADVISORS, LTD. 2,352,900$63,458,0001.42%
SCGE MANAGEMENT, L.P. 588,235$15,865,0000.79%
View complete list of BRIDGEBIO PHARMA INC shareholders